Rosen Law Firm has announced a class action lawsuit against uniQure N.V. on behalf of shareholders who purchased ordinary shares between September 24, 2025, and October 31, 2025. The lawsuit alleges uniQure misrepresented its business operations, specifically regarding FDA approval for its Pivotal Study design and the need for additional studies affecting its Biologics License Application timeline. Shareholders with significant losses are encouraged to contact the firm to learn about their rights and to potentially serve as lead plaintiff before April 13, 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm has announced a class action lawsuit against uniQure N.V. on behalf of shareholders who purchased ordinary shares between September 24, 2025, and October 31, 2025. The lawsuit alleges uniQure misrepresented its business operations, specifically regarding FDA approval for its Pivotal Study design and the need for additional studies affecting its Biologics License Application timeline. Shareholders with significant losses are encouraged to contact the firm to learn about their rights and to potentially serve as lead plaintiff before April 13, 2026.